Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 8/20 | 0.50 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 4/20 | 0.42 |
| ▸ | STK4 | Q13043 | 1/20 | 0.42 |
| ▸ | STK3 | Q13188 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1792276 | 0.92 | RPS6KB1 (0.56) | RPS6KB1LIMK2MAPTTP53KIT | |
| SCHEMBL4932503 | 0.84 | RPS6KB1 (0.54) | RPS6KB1MAPTTP53STK4STK3 | |
| Hydrochloric Acid SCHEMBL4932382 | 0.83 | RPS6KB1 (0.53) | RPS6KB1MAPTTP53STK4STK3 | |
| Trifluoroacetic Acid SCHEMBL4922031 | 0.83 | RPS6KB1 (0.51) | RPS6KB1MAPTTP53KIT | |
| SCHEMBL1793033 | 0.83 | RPS6KB1 (0.51) | RPS6KB1MAPTTP53 | |
| SCHEMBL1788672 | 0.83 | RPS6KB1 (0.58) | RPS6KB1MAPTTP53 | |
| SCHEMBL1792457 | 0.83 | RPS6KB1 (0.62) | RPS6KB1MAPTTP53KITSTK4 | |
| Hydrochloric Acid SCHEMBL4931091 | 0.82 | RPS6KB1 (0.51) | RPS6KB1MAPTTP53 | |
| SCHEMBL2296396 | 0.82 | RPS6KB1 (0.57) | RPS6KB1MAPTTP53STK4STK3 | |
| Hydrochloric Acid SCHEMBL4922679 | 0.82 | RPS6KB1 (0.57) | RPS6KB1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1750727-A2 | KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005117909-A2 | KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | RPS6KB1 13/4885LIMK2 589/4885MAPT 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.